Another phase III trial (FURVENT, NCT05607550) is currently in progress, which aims to compare the safety and efficacy of furmonertinib with platinum-based chemotherapy in treatment-naïve patients with locally advanced or metastatic nonsquamous NSCLC harboring EGFR exon 20 insertion mutations [178]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.